Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422171 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19CYP1B1KEAP1 | |
| SCHEMBL25265325 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19CYP1B1KEAP1 | |
| SCHEMBL25437935 | 0.86 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19KEAP1MIF | |
| SCHEMBL24174313 | 0.86 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19KEAP1MIF | |
| SCHEMBL30533783 | 0.86 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19KEAP1MIF | |
| Bromide SCHEMBL31181787 | 0.85 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19KEAP1MIF | |
| Hydrochloric Acid SCHEMBL31181780 | 0.85 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19KEAP1MIF | |
| Bromide SCHEMBL28576583 | 0.85 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19KEAP1MIF | |
| Bromide SCHEMBL28576581 | 0.85 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19KEAP1MIF | |
| SCHEMBL24175264 | 0.84 | KDM4E (0.40) | KEAP1KDM4ENFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| WO-2021214472-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | CYP1A2 153/4885CYP2C9 1200/4885CYP2C19 1332/4885 |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | CYP1A2 527/4885CYP2C9 2153/4885CYP2C19 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.